• Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone
• The project gathers some of the world’s leading researchers in female sexual desire and psychedelics
• This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications
• Clinical trials of MDMA as a treatment for PTSD have shown some success due to targeting the pathways that process fear
• MINDCURE is working with a molecule that will be first-to-market – MDMA is predicted to be approved by 2023 – this brings them closer to the money

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a diversified life sciences company currently at the forefront of innovating and improving mental health through the research and use of psychedelic compounds, is pleased to announce the launch of its “Desire Project” to address and treat female Hypoactive Sexual Desire Disorder (“HSDD”) with MDMA-assisted psychotherapy. The Desire Project is the first-of-its-kind study targeting this sexual disorder which affects an estimated 9.5 million premenopausal women in the United States alone. The benefits of the study could potentially impact women and relationships on a worldwide level (https://ibn.fm/uC78c). HSDD is a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. According to current estimates, 40% of women in the US have self-reported low sexual desire, with HSDD affecting 10% of adult women and 14% of premenopausal adult women. Men can also suffer from HSDD. “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way. We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind,” MINDCURE President and CEO Kelsey Ramsden said. “Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire.” In clinical trials using MDMA, some success has been shown in post-traumatic stress disorder (“PTSD”) patients. The MDMA treatment works on the brain’s pathways related to fear. It can help enhance fear memory extinction, modulate fear memory reconsolidation, and even bolster the social behavior in animal tests. MINDCURE has spent six months planning the upcoming Desire Project with a strong emphasis on how MDMA may ease some of the fear factors in women, which could play a large role in female-related sexual disorders that are not currently treatable by methods or medications on the market. The Desire Project comprises some of the world’s leading researchers in female sexual desire and psychedelics. These world-renowned names include:

• Dr. Anita Clayton (Professor and chair of the Department of Psychiatry and Neurobehavior Sciences and a Professor of Clinical Obstetrics and Gynecology at the University of Virginia), Dr. Jennifer Mitchell (lead author of MAPS MDMA-assisted therapy for PTSD study),
• Dr. Cindy Meston (directs the Female Sexual Psychophysiology Laboratory at the University of Texas in Austin),
• Dr. Robert Pyke (leader of the Addyl project, a drug used to treat the symptoms of HSDD and has author of over 100 peer-reviewed publications in the last 18 years), and
• Dr. Sherry Walling (a practicing, licensed clinical psychologist with a master’s degree in theology and emphasis on trauma).

“During my decades as a psychiatrist, I’ve seen first-hand the limitations of existing treatments. This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder,” Mind Cure Health CMO Dr. Joel Raskin, MD, said (https://ibn.fm/4MJOp). Living with HSDD can damage the lives of the women it affects, causing depression and anxiety – potentially destroying personal relationships. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from this disorder. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• What: USA CBD Expo 2021
• When: October 28-30, 2021
• Where: Chicago, Illinois
• Details on the Venue: Hosted at the famous McCormick Place convention center in downtown Chicago
• Key Stats: 50+ field experts, 300 unique vendors, and thousands of high-quality products from all over the globe

The skyrocketing global CBD and hemp markets have only continued to dominate the industry after the COVID-19 pandemic. Now, professionals from around the world can finally come together to discuss the knowledge, experience and advice they’ve acquired this past year at the USA CBD Expo 2021 in Chicago, Illinois. The event is hosted from October 28-30 at the famous McCormick Place convention center and is considered the largest CBD expo series in the nation. The massive 2 billion dollar venue space and recent advances for cannabis legalization in Chicago makes it the perfect setting for this global CBD showcase (https://ibn.fm/1AoKh). The windy city also hosts massive market potential for the CBD and hemp industry due to foot traffic alone, as more than 58 million travelers visit the windy city each year. Additionally, since its legalization, retail cannabis sales within the state have skyrocketed to an estimated $40 million in revenue. In addition to the city’s impressive statistics, the convention center is conveniently located near several luxury lodgings already blocked out for the event, like the Hilton Garden Inn and Home2 Suites. The convention’s presentation sponsor, 3Chi, stays at the forefront of this booming industry by creating a professional gathering for experts and business owners from various fields of CBD and hemp. The American-made company prides itself on its biochemist formulated and lab-tested hemp products. Their impressive list of participants includes more than 50 experts in the CBD and hemp field and hundreds of unique vendors displaying thousands of high-quality products. The scheduled talks range from marketing and finance to niche topics like sports medicine, sustainability, farming, and even animal medicine. Some of the highly anticipated talks include actor Jason Gann from Wilfred Hemp & CBD and Wilfred Cannabis, Scott Frohman and The Power of Medicinal Mushroom Extracts, as well as discussions surrounding delta-8, psychedelic education, and CBD for sexual wellness. Four possible ticket types are available for the convention, ranging from Industry Buyer and Industry Professional passes to General Admission and Press passes. Each ticket type has applicable perks and most choices encompass the entire three-day event to professional networking opportunities. Additionally, vendors may receive a discount if they sign up for multiple days of the event. Tickets for the Chicago showcase are available for purchase on the event’s website (https://ibn.fm/FeBYp). For further information about USA CBD Expo 2021 or to learn how to buy tickets, visit the event’s website at https://usacbdexpo.com

• Plant-based food retailer and community builder PlantX Life Inc. is tapping into a growing consumer market focused on health and longevity, providing education and other resources to help make plant-based community goals more accessible
• PlantX Life maintains a digital presence that includes a weekly podcast series, YouTube channel videos, an informative blog and an e-commerce portal accessible through Walmart’s and Amazon’s Marketplace
• The company is preparing to open a store and affiliated website in United States in October and Israel in November to add to its brick-and-mortar presence in Canada     PlantX Life sells over 5,000 products and eventually expects to consistently add new       items and brands to its offerings

One-stop shopping plant community brand builder PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) continues to passionately pursue its mission not only through a growing retail presence, but by establishing an ecosystem that preaches the virtues of plant-based living and the increasingly supportive community arising from common plant lifestyle interests as well. PlantX’s vodcast series provides weekly insights into vegan products, athletes who thrive on a plant-based diet, and industry trends. With season 2 well under way, the “vodcast” recently featured interviews with tennis star Venus Williams and Two Bears co-founder David Schneiderman, whose company sells oat milk lattés, coffee, and oat milk (https://ibn.fm/XvYdC). Through its YouTube channel (https://ibn.fm/56AsQ). PlantX provides upbeat how-to videos for recipes and fitness practices, as well as news about the state of the industry and PlantX’s investor relations. And the company’s blog provides the mortar for binding PlantX’s community of vegan lifestyle interests together with education to make consistency in beneficial habits more accessible (https://ibn.fm/PULUB). “Over the last 10 years I’ve learned that a plant-based diet is a major part of wellness and longevity,” PlantX founder Sean Dollinger said in a video shared this summer about his journey toward a healthier lifestyle. “Don’t feel like you have enough time to prepare healthy food? We’ll deliver plant-based meals right to your door. But it’s not all about food. There are health benefits of having plants in your home and they’re great for home decor and gifts. We also want to help you find the best plant-based restaurants, interact with others in the plant-based community, share ideas and grow together.” As the digital hub of a thriving plant-based market ecosystem, the company sells more than 5,000 plant-based products across North America and anticipates an ongoing expansion of its product lines. In September, PlantX announced a number of initiatives that will expand awareness of its profile. The company will launch as a seller on Amazon Marketplace (https://ibn.fm/Iy9m7) and on Walmart’s Marketplace in the United States after a successful entry on the Walmart Marketplace in Canada (https://ibn.fm/plRwx). The company has already opened a brick-and-mortar store in Squamish, British Columbia, and will open additional physical stores in San Diego in October, and Tel Aviv in November. Additionally, the company will launch an Israel-based website in conjunction with its store there. All of the company’s physical stores will be rebranded as XMarket (https://ibn.fm/wc66z). “We’re here as a resource and hopefully we can give you a healthier and longer life. You can’t put a price tag on that,” Dollinger said. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Thursday- October 21, 2021 Venue- Wyndham Grand Hotel, Jupiter, FL The Dawson James Securities’ 6th Annual Small Cap Growth Conference is being held on October 21st 2021 at the scenic Wyndham Grand Hotel, Jupiter, Florida. Small-cap industries, company executives, and investors from the healthcare, technology and consumer sectors are invited to attend this Small Cap Growth Conference. There is no fee for attendees. Since 2004, Dawson James Securities, an investment banking firm with offices in New York, Florida and Maryland has propelled small and microcap public and private growth companies towards growth and lucrative investment opportunities. This 6th annual Small-cap growth conference is focused on providing a unified platform for senior leadership from approximately 40 small-cap growth companies and 12 leading industry sponsors to communicate and develop productive business relationships with institutional funds, family offices and high net-worth investors. The event will feature keynotes and discussions from industry leaders and accredited investors about the trends and the future of investment and growth in the small-cap industries of the healthcare, consumer, and technology segment. 40 participating companies will be  showcased on the 21st with a 2-track presentation format about the nature and prospect of their business and potential benefits of association. Dawson James Securities organizes these conferences for the benefit of small and microcap industries. The format allows potential investors to hear the presenting companies’ stories first hand and to interact directly with senior leadership teams.  This conference specifically targets small and microcap industries that seek exposure and better investment opportunities. Entrepreneurs, startups, and small industries can leverage this conference platform to reach out to investment firms and get discovered by distinguished sponsors to develop long-term networking and business alliances. The event will commence with registration and breakfast promptly at 8:00 a.m. on Thursday, Oct. 21, 2021, followed by corporate presentations, discussions from industry leaders, and one-on-one management meetings. To know more about the event https://ibn.fm/GlnPH.

• Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology
• DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents
• The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption
• DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol

Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as recently as 2013 (relative to the mid-19th century origin of the modern pharmaceutical industry), the taste-masking of oral solid dosage forms was still a major challenge that needed to be addressed by formulation or pharmaceutical scientists (https://ibn.fm/7wmaW). The most commonly used taste-masking methods at that time were film coating and the use of sweeteners, sugars, or flavors, but the latter is considered ineffective due to its inability to adequately mask the bitter taste. Still, less conventional methods such as microencapsulation, spray drying, supercritical fluids, and more had already been reported as successful taste-masking techniques. Since then, Lexaria Bioscience (NASDAQ: LEXX), a global innovator whose patented DehydraTECH(TM) drug delivery technology could potentially improve oral administration of Active Pharmaceutical Ingredients (“APIs”), has led the pharmaceutical industry in advancing novel taste-masking techniques. With part of its R&D having progressed from animal studies to human clinical studies, the company has so far established that DehydraTECH masks unwanted taste, thereby eliminating the need for sugar-filled edibles; improves the speed of drug onset; increases the effectiveness of drug delivery into the bloodstream (bioavailability); and boosts brain absorption (https://ibn.fm/la1J9). DehydraTECH’s taste-masking capabilities result from the use of fatty acids. The technology combines the API with fatty acids, such as long-chain fatty acid (“LCFA”), before applying the resultant compound to food/carrier particles (substrate material), performing dehydration synthesis procedure, and, finally, rendering it as powder or liquid for use in desired final form factor. Importantly, according to an evaluation LEXX conducted in collaboration with National Research Council, the largest R&D organization in Canada, DehydraTECH does not alter the chemical structure of the API. The fatty acids offer dual benefits. First, they are believed to block and divert bound APIs away from bitter taste receptors, essentially rendering them flavorless, as well as odorless. “DehydraTECH formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking, allowing manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners,” reads the company’s website (https://ibn.fm/TfY0x). The LCFA also promotes quick absorption into lymphatics, bypassing the first-pass liver effect, which drastically reduces the bioavailability or overall effectiveness of orally ingested drugs. In this regard and based on findings of clinical testing, DehydraTECH significantly increases bioavailability for fat-soluble drugs. DehydraTECH has so far been evaluated as part of nicotine, antivirals, and cannabinoids (“CBD”) R&D programs. The nicotine program showed that the drug delivery platform significantly increased the quantity of nicotine delivered. It was also responsible for 295% higher brain levels of nicotine compared to controls. Additionally, its first 2021 human clinical study under the CBD program, HYPER-H21-1, has evidenced a rapid and sustained decline in blood pressure, with the reduction being more pronounced in the first 10 to 50 minutes of the study. The second 2021 human clinical study, HYPER-H21-2, has demonstrated up to 23% drop in blood pressure with DehydraTECH-CBD compared with placebo. Though Lexaria still awaits additional analyses, its drug delivery technology has proven useful for potentially treating hypertension. Thirdly, its antiviral program, featuring cell-based and animal studies using Remdesivir and antiviral drugs being investigated for SARS-CoV-2 and HIV/AIDS, has demonstrated enhanced drug delivery. Since it began developing DehydraTECH in 2014, Lexaria has significantly strengthened and broadened the technology to an unprecedented degree. Even so, more may still be in the offing for the company currently disrupting the pharmaceutical industry. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study
• The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients
• According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months
• Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803

During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing novel bioscience solutions for conditions with high unmet need, expressed its expectation to initiate at least two Phase 2a clinical trials in Q4 2021 (https://ibn.fm/H85KV). The trials, to be conducted at the University of Florida under the guidance of Dr. Jennifer Miller, a pediatric eating disorders expert and the trials’ principal investigator, will evaluate TRP-8802, Tryp’s oral formulation of synthetic psilocybin, in combination with psychotherapy. The company announced September 22 that it had submitted to the US Food and Drug Administration (“FDA”) an Investigational New Drug (“IND”) application to evaluate TRP-8802 in the Phase 2a study for the treatment of patients with eating disorders (https://ibn.fm/ze4vd), acting as its first major clinical development milestone. According to Dr. Miller, the submission represents hundreds of hours of preparation, design, and coordination as Tryp and its partners “pursue a leading-edge treatment of psilocybin with psychotherapy.” Part of the efforts Dr. Miller was alluding to include collaborations with Clinlogix, a contract research organization (“CRO”), the University of Florida, and Fluence, a psychedelic therapy educational platform. In late August, Fluence undertook and completed the training of psychotherapists who will take part in the trial by overseeing dosing sessions (https://ibn.fm/7G3Ri). On its part, Clinlogix will support the upcoming Phase 2a clinical trials by providing medical writing, biostatistical analysis, data management, and trial monitoring (https://ibn.fm/BP4YW). The submission sets the stage for the Phase 2a clinical trial subject to a favorable review by the FDA. The study is expected to enroll 10 patients with various overeating disorders, such as hypothalamic obesity, binge eating disorder, and Prader-Willi Syndrome. The administration of TRP-8802 is expected to enhance neuroplasticity and help create healthy neural patterns associated with hunger and eating. Prior to the administration, the patients will meet with the trained psychotherapists for two sessions. The psilocybin will then be administered during two drug-dosing sessions, after which integration sessions will follow. “This IND submission marks the most important milestone the company has achieved to date and will be critical in identifying patient responses to the active ingredient, consistent with that of our proprietary drug candidate, TRP-8803, that will be used in Phase 2b trials and beyond,” said Tryp Chairman and CEO Greg McKee. McKee also noted that the submission is the first of several IND filings the company expects to make in the coming months, further reiterating that Tryp is eager to begin enrolling its first patients in multiple Phase 2a trials later this year. For Tryp, this is only the beginning. The company intends to use TRP-8803, its proprietary psilocybin-based drug product manufactured exclusively for Tryp, for Phase 2b clinical trials, and beyond. It has already announced partnerships with the University of Michigan, Calvert Labs, and Gad Consulting to conduct bridging studies in preparation for Phase 2b clinical trials, with more collaborations possibly still in the works. In this regard, the clock has begun counting what will likely be hundreds of additional hours of preparation, design, and coordination in readiness for the Phase 2b trials. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs
• In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter
• In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers
• The Sapientus platform creates proprietary matrices for assessing consumer risk potential using context-based outlooks in accordance with established behaviors

The development of business capabilities to harvest and apply big data insights is affecting revenue streams that vary in size and impact from national government contractors (https://ibn.fm/yE6s6) to farmers harvesting their fields (https://ibn.fm/Vqw3t). Industry e-magazine Datamation reported Sept. 26 on Splunk findings that “organizations with ‘mature data practices’ release twice as many products and increase employee productivity at double the rate of organizations with less mature data practices” (https://ibn.fm/kQuHI). Big data communications technology innovator FingerMotion (OTCQX: FNGR) is focusing its new platform on China’s insurance market as the nation serving as the home to some 1.4 billion people continues to build a powerful economy on the efforts of factories crucial to the global supply chain. FingerMotion launched its Big Data Insights division with its flagship database IP Sapientus last year and attracted global insurance behemoth Pacific Life Re-insurance as a client interested in developing a customer base within China. Sapientus is a stand-out technology that applies publicly available data to clients’ risk forecast needs, generating proprietary matrices that assimilate information on individuals’ behaviors to create context-based outlooks for customers. It’s a service that’s particularly attractive in China since the country’s credit and insurance risk standards are still in a developmental stage and Sapientus can help provide an alternative means of judging potential liabilities for a corporate client. During the past year, FingerMotion’s revenues have seen steady growth, largely due to mobile communications services, and the Pacific Life agreement earlier this year positioned it for an even more promising future.  CEO Martin Shen said during a corporate update conference call discussing the company’s first-quarter financial results in August that FingerMotion’s top-up business had risen 341 percent and mobile SMS and MMS services had increased by 77 percent, and that “some significant funds” raised after the quarter ended will likely lead to a higher outcome on the balance sheet once the Q2 report is completed. “Most of the e-commerce companies operate in the red for quite a while before they turn a profit, but our current trajectory has us moving in that profitable direction a bit quicker than maybe other companies have been,” Shen said (https://ibn.fm/OPdc3). Shen acknowledged that the company has considered eventually focusing its big data platform on other industries beyond insurance and in markets beyond China’s borders, but said the company needs to stay focused on its immediate purpose before expanding its reach. “We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets. … But again, that takes time to develop, and we’re really still developing what we’re doing right now in China,” Shen said. “Right now, let’s just build and make sure that our foundation is strong first.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Some social media platforms, like TikTok, pay artists for their music, but the amounts are insignificant, and an artist’s musical track would have to be used hundreds of thousands of times to make a decent profit
• Friendable’s Fan Pass Live provides artists an online platform to share their music content and earn a profit
• Artists earn on Fan Pass through fan subscriptions, merchandise sales, ticket sales, and more
• Fan Pass artists have access to Pro Services that include logo design and merchandise, as well as social media promotions for upcoming events

2020 was a year of change (and growth) for the music industry. Streaming replaced in-person shows, and artists were forced to adapt and evolve to stake a piece of the revenue. Fast-forwarding to today, live streaming shows and other events are the new normal. More and more artists are entering the virtual stage without representation, simply going online to do what they love and earn money in the process. Artists don’t have to rely solely on social media platforms like TikTok, with revenue structures that constantly change, to gain recognition for their craft. For example, TikTok does pay its artists revenue, but it is based on the number of times their song is used to make a video. Each time the track is used to create a video, it is considered a “creation,” the metric value in which TikTok measures popularity for revenue purposes. To make a living off of TikTok alone, artists would need to secure hundreds of thousands of creations each month (https://ibn.fm/lRrAB). A more attractive and lucrative revenue-generating option available for up-and-coming artists is the Fan Pass platform, launched in July 2020 by Friendable (OTC: FDBL). On the Fan Pass streaming artist platform, artists can build up a fan base, gain access to merchandising, and earn revenue while doing what they love. Each artist has the opportunity to earn revenue from the monthly subscription fee that fans pay to gain access to the Fan Pass artist catalog, merchandise purchases, and even 100% of ticket sales for exclusive live-streamed content and videos on-demand. Artists also have access to premium equipment available for purchase and exclusive Artist Pro Services. The Artist Pro Services are offered in three tiers – basic, standard, and a premium-style option. Each is priced accordingly and offers artists options for logo design, merchandise designs, and marketing material. The process is easy to get started. Artists fill out a form answering survey questions, the prototype is created, and artists then communicate what they like, don’t like, or want to be changed. Packages are even available for social media promotion of upcoming events. Prices range from $45 for a social ad/announcement design to promote the next three events to a $400 pro merch collection with five high-resolution designs placed in the store on any five merchandise items available. Friendable is currently implementing a 120-day plan that strategizes growth for the Fan Pass platform. The company has already accomplished creating and releasing version 2.0 of the platform, gaining acceptance from the Apple Store and Google Play Store for the new application, and launching a brand awareness campaign, among others. Additionally, Fan Pass has begun promoting Pro Services to help artists receive revenue for doing what they love. With this approach and the wealth of services and benefits available, Fan Pass is in a unique position to disrupt the music streaming market, an expanding sector that is growing in value from $20.6 billion in 2019 to an anticipated $60.5 billion by 2026 (marking a CAGR of 16%). The immediate increase for this market segment is due to the increased availability of the internet and access to online content through services like Fan Pass (https://ibn.fm/gw0Vq). For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• FuelPositive recently appointed André Mech as the company’s Strategic Carbon Credit and Emissions Reduction Specialist
• The company also brought Sussex Strategy Group on board to offer government relations services
• So far in 2021, FuelPositive has achieved several milestones, including acquisitions, initial licensing agreements, the commencement of and ultimate completion of phase II build-out
• Going forward, it is building its first systems to be used in demonstration projects in 2022, while it seeks to ramp up production capacity for the 2022 fiscal year

2021, so far, has been an excellent year for FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF). Since holding its first investor presentation back in June 2021, the company has achieved several other milestones and made strategic investments. Combined, these bring it even closer to its ultimate goal of providing sustainable, clean energy to reduce carbon emissions. FuelPositive’s Chief Executive Officer (“CEO”) and Chair of the Board, Ian Clifford, recently appeared on its YouTube channel to highlight the company’s recent developments and offer insights into its future (https://ibn.fm/q6gNg). Of note was the move to bring on board André Mech, who would assume the position of Strategic Carbon Credit and Emissions Reduction Specialist. Focusing on carbon-free ammonia is a lucrative move by FuelPositive, allowing it to monetize carbon credits by selling them through different exchanges around the world (https://ibn.fm/RDzdM). Mr. Clifford, however, has acknowledged that this is a complicated process that requires someone who knows how to approach and effectively deal with it. With his years of experience, Mech would help the company navigate the industry and achieve this goal. He would be lending his years of experience from advising governments and organizations on sustainability, energy efficiency, and carbon reduction, thereby helping FuelPositive sell its carbon credits in the same way that Tesla does. Mr. Clifford also touched on hiring Sussex Strategy Group to offer government services. Like André Mech, this organization would help FuelPositive navigate the government landscape, securing partnerships and funding for projects that will prove FuelPositive’s technology and ultimately help governments achieve, or even surpass the promises of the Paris Agreement (https://ibn.fm/wr1gO). To date, FuelPositive has managed to achieve three main milestones for the 2021 fiscal year: process determination, primary component vendor selection and procurement, and engineering design. These milestones touch on most of the company’s activities, including but not limited to major component design, the fabrication of reactors, and ammonia separation modeling and design (https://ibn.fm/OAK7F). The company has also made some notable acquisitions and begun the build-out of Phase II systems (https://ibn.fm/DMbXC). Going forward into 2022, the company plans to put systems in place for demonstration projects with partners and ramp up production capability in the early half of the year, and start shipping commercial systems in the last quarter of 2022. The hydrogen economy is at the core of FuelPositive’s agenda. Through its carbon-free ammonia, the company offers a solution that requires 30% less energy than conventional ammonia production, with zero carbon emissions. FuelPositive can also store 65% more hydrogen in its carbon-free NH3 than traditionally highly compressed hydrogen, making hydrogen easy to store and transport using existing infrastructure, and differentiating the company from its competitors (https://ibn.fm/K63kr). The global green ammonia market size is projected to post a 54% year-over-year growth between 2020 and 2025 (https://ibn.fm/rZb92). With FuelPositive spearheading the modular and scalable carbon-free ammonia industry, the company plans to bank on the opportunities therein and be part of this imminent growth. So far, the company’s systems and infrastructure place it in a great position to achieve this and other target milestones set for the coming financial year, something that Mr. Clifford has expressed optimism and enthusiasm for. FuelPositive believes that carbon-free ammonia is the future. All strategic decisions made in 2021 have taken the company steps closer to realizing a world with sustainable, clean energy that replaces fossil fuels. The company’s future looks bright, and its role in pushing for the change from fossil fuels cannot be ignored. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Ideanomics has entered into an agreement with the founders of Energica, embodying plans to increase its stake to 70%
• The renewed investment interest further extends IDEX’s resolve to expand its global footprint in the EV industry
• Energica is the manufacturer of high-performance all-electric motorcycles
• Ideanomics will participate at the upcoming MOVE America event, scheduled for September 28-30, where it will showcase technologies from WAVE and Energica

Ideanomics (NASDAQ: IDEX), a global company that facilitates the adoption of commercial electric vehicles (“EVs”) and supports next-generation financial services and fintech products, announced September 15 that it has entered into an agreement to launch a voluntary conditional tender offer together with the founders of Energica Motor Company S.p.A (“Energica”). The offer will see IDEX increase its stake to 70%, while the founders shall continue to own 29% of the Italy-based company, subject to regulatory approval and other closing conditions (https://ibn.fm/fzYmb). The recent announcement comes about six months after Ideanomics acquired a 20% stake in Energica, a manufacturer and distributor of high-performance 100% battery-powered motorbikes (https://ibn.fm/CSgsH). At the time, the investment represented IDEX’s resolve to expand its global footprint in the EV industry and complemented Treeletrik’s operations in the ASEAN market. Ideanomics purchased a controlling stake in the sales and distribution arm of Treeletrik, a Malaysia-based manufacturer of all-electric motorcycles, in March 2019 (https://ibn.fm/L6Ki2). The renewed investment interest, as captured by the recent agreement, therefore extends this resolve even further. “We are grateful for Energica’s continued interest in growing synergistically alongside other brands within the Ideanomics Mobility ecosystem,” commented Ideanomics CEO Alf Poor (https://ibn.fm/poF0l). “With exceptional management and leadership in place and a full range of innovative zero-emissions products already in the market, we believe Energica has the opportunity to benefit strongly from Ideanomics Capital’s resources, transforming their growth trajectory and positioning them as a global leader in the electric motorcycle market.” Manufactured in historic Modena, the heart of the Italian Motor Valley, Energica motorcycles are the ultimate embodiment of the Italian design, performance, and exclusivity. Thanks to their state-of-the-art, race-derived technology, they boast the highest emissions-free peak and sustained performance of any road-legal electric motorcycle. It is no wonder that they have been a hit among motorcycle enthusiasts, as seen through Energica’s sales statistics. In 2020, the company nearly doubled its sales, while 2021 has seen the manufacturer accept its largest order to date. This growth trajectory may continue well into the future, especially in the wake of a Technavio market research report, which anticipates that the high-performance electric motorcycle market will grow at a CAGR of more than 35% between 2020 and 2024, with Europe accounting for about 39% of the overall growth (https://ibn.fm/VcVtH). “The two-wheeler electric market is poised for significant growth, and we couldn’t be more excited about the synergies between Ideanomics and Energica that will allow us to be a prime player in this space,” said Ideanomics’ Executive Chairman, Shane McMahon. Part of these synergies will be on display at an upcoming global showcase event for urban mobility discussions and solutions, MOVE America, in which Ideanomics will be a participant (https://ibn.fm/CUI2A). Ideanomics will showcase technologies from WAVE, a wireless charging provider allowing commercial fleet operators to extend the range of medium- and heavy-duty EVs with 125kW to 500kW charging systems, and Energica. The event will be held from September 28 to 30 at the Palmer Events Center in Austin, Texas. On September 28 at 10.40 am CT, WAVE CEO Aaron Gillmore will give a keynote presentation about overcoming fleet electrification barriers with wireless charging for the bus transportation sector. Later in the day, at 1:00 pm, he, in concert with Kate Lam, Ideanomics’ Managing Director of Financial Products, will lead a roundtable discussion on fleet electrification challenges. Thereafter at 2:55 pm, WAVE CTO Michael Masquelier will participate in a Truck Tech Panel. “MOVE is an opportunity for Ideanomics and our operating companies like Energica and WAVE to talk more about the things we are doing in the fleet electrification space that matter,” said Alf. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX